.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Daiichi Sankyo
Dow
AstraZeneca
Mallinckrodt
US Department of Justice
Johnson and Johnson
QuintilesIMS
Express Scripts

Generated: September 20, 2017

DrugPatentWatch Database Preview

Janssen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?

JANSSEN PHARMS has fifty-six approved drugs.

There are thirty-seven US patents protecting JANSSEN PHARMS drugs and there have been three Paragraph IV challenges on JANSSEN PHARMS drugs in the past three years.

There are seven hundred and eighty patent family members on JANSSEN PHARMS drugs in fifty-seven countries.

Summary for Applicant: Janssen Pharms

Patents:37
Tradenames:54
Ingredients:34
NDAs:56
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-004Aug 8, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-003Feb 28, 2001ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
TOPAMAX
topiramate
CAPSULE;ORAL020844-002Oct 26, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-002Jul 31, 2009RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-002Aug 8, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-002Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
ORTHO-NOVUM 7/7/7-28
ethinyl estradiol; norethindrone
TABLET;ORAL-28018985-002Apr 4, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-003Aug 8, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
CONCERTA
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-003Sep 20, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-003Apr 2, 2003► Subscribe► Subscribe
Janssen Pharms
TOPAMAX
topiramate
TABLET;ORAL020505-005Dec 24, 1996► Subscribe► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-002Feb 28, 2001► Subscribe► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-003Apr 1, 2005► Subscribe► Subscribe
Janssen Pharms
ORTHO TRI-CYCLEN LO
ethinyl estradiol; norgestimate
TABLET;ORAL-28021241-001Aug 22, 2002► Subscribe► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003► Subscribe► Subscribe
Janssen Pharms
NIZORAL
ketoconazole
SHAMPOO;TOPICAL019927-001Aug 31, 1990► Subscribe► Subscribe
Janssen Pharms
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
levofloxacin
INJECTABLE;INJECTION020635-005Dec 20, 1996► Subscribe► Subscribe
Janssen Pharms
CONCERTA
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET, ORALLY DISINTEGRATING;ORAL021444-001Apr 2, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JANSSEN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
canagliflozin
Tablets100 mg and 300 mg
INVOKANA
3/29/2017
canagliflozin andmetforminhydrochloride
Tablets50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg
INVOKAMET
3/29/2017
rivaroxaban
Tablets10 mg, 15 mg, and 20 mg
XARELTO
7/1/2015
itraconazole
Oral Solution10 mg/mL
SPORANOX
5/3/2013
levofloxacin
Oral Solution25 mg/mL
LEVAQUIN
7/30/2009
norelgestromin and ethinyl estradiol
Transdermal System0.15 mg/0.02 mg per 24 hours
ORTHO EVRA
3/22/2007
galantamine hydrobromide
Extended-release Capsules16 mg and 24 mg
RAZADYNE ER
3/11/2006
galantamine hydrobromide
Extended-release Capsules8 mg
RAZADYNE ER
3/2/2006
almotriptan malate
Tablets6.25 mg and 12.5 mg
AXERT
12/8/2005
topiramate
Tablets50 mg
TOPAMAX
9/8/2005
topiramate
Capsules15 mg and 25 mg
TOPAMAX SPRINKLE
9/7/2005
methylphenidate hydrochloride
Extended-release Tablets18 mg*, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
metformin hydrochloride
Extended-release Tablets18 mg, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
risperidone
Orally Disintegrating Tablets0.25 mg
RISPERDAL
4/11/2005
risperidone
Orally Disintegrating Tablets3 mg and 4 mg
RISPERDAL
3/23/2005
galantamine hydrobromide
Tablets4 mg, 8 mg and 12 mg
RAZADYNE
2/28/2005
topiramate
Tablets25 mg, 100 mg and 200 mg
TOPAMAX
12/26/2001

Non-Orange Book Patents for Janssen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,696,091 Pharmaceutical composition of topiramate► Subscribe
8,323,691Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
7,576,111Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
7,935,674Indole derivatives► Subscribe
7,511,021Substituted indazole-O-glucosides► Subscribe
6,905,654 Method and apparatus for reducing static charges during polymerization of olefin polymers► Subscribe
7,511,022Substituted indole-O-glucosides► Subscribe
6,110,503 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent► Subscribe
6,809,107 Neurotrophic pyrrolidines and piperidines, and related compositions and methods► Subscribe
8,936,810Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen Pharms Drugs

Country Document Number Estimated Expiration
Norway333360► Subscribe
Taiwan200529859► Subscribe
Poland330431► Subscribe
Spain2300845► Subscribe
World Intellectual Property Organization (WIPO)0191720► Subscribe
Spain2259481► Subscribe
Japan5133495► Subscribe
Taiwan200422299► Subscribe
Canada2534024► Subscribe
Austria318605► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008018,C1261606Lithuania► SubscribePRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008, 0080930
497Luxembourg► Subscribe91497, EXPIRES: 20230930
C/GB07/065United Kingdom► SubscribePRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
2014 00016Denmark► SubscribePRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
0670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
6Finland► Subscribe
2014000024Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Covington
Healthtrust
Daiichi Sankyo
US Department of Justice
Fuji
Cantor Fitzgerald
Cipla
Novartis
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot